You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
21 November 2024
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
7 November 2024
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
30 October 2024
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
16 October 2024
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
9 August 2024
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
25
Nov 24
Analysts’ Conference
Half-yearly financial statements 2024
28 March 2024
Annual financial statements 2023
10 August 2023
Half-yearly financial statements 2023
13 November 2024
Original-Research: APONTIS PHARMA AG (von Montega AG): Verkaufen (zuvor: Halten)
18 October 2024
Original-Research: APONTIS PHARMA AG (von Montega AG): Halten (zuvor: Kaufen)
16 August 2024
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
12 August 2024
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
24 June 2024
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
15 May 2024
